Free Daily Podcast Summary
Conversations in Drug Development: Daily Summaries Delivered
by Boyds
Welcome to Conversations in Drug Development, brought to you by the team at Boyds. This podcast is for our fellow community of scientists and clinicians working in the wonderful world of cell and gene therapy and drug development.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 3 weeks ago17 min
Ada Lovelace Day: Breaking Barriers, Shaping Futures
To celebrate Ada Lovelace Day, women from Boyds share their career journeys, the challenges they’ve overcome and their advice for the next generation of women in science.
- 4 weeks ago37 min
EU Pharma Reform 2026: What Every Developer Needs to Know
In this episode, Katherine Bowen and Shalini Gupta discuss the EU pharmaceutical legislation reform — a comprehensive update to regulations and directives that will affect drug approval, orphan and paediatric rules, exclusivity incentives, EMA structure and timelines, supply obligations, environmental risk assessments, and transparency requirements. Hosts outline the timeline, key practical impacts for sponsors, and recommended next steps: begin preparing now, align regulatory, market‑access and supply strategies, and monitor EMA guidance during the transition period.
- Jun 22, 202632 min
Live Biotherapeutics: Navigating the Next Frontier in Drug Development
In this episode, Boyds' experts explore the emerging field of live biotherapeutic products (LBPs), explaining what they are, how they differ from everyday probiotics, and their roots in microbiome-based therapies, including fecal microbiota transplantation (FMT). Katherine and Celine discuss the evolving regulatory landscape, comparing the FDA's guidance and recent approvals with the more cautious approach taken by the EMA and national authorities across Europe. They also examine the scientific, manufacturing, and clinical development challenges facing LBP developers, including product consistency, mechanism of action, safety considerations, and clinical trial design.
- Apr 8, 202625 min
UK Clinical Trial Regulation: What Sponsors Need to Know About UK CTR 2025
In this episode, experts at Boyds, Chris Moore and Shalini Gupta break down the UK Clinical Trial Regulation (UK CTR), exploring why the reform was introduced and highlighting the practical changes sponsors need to know - including new terminology, updated timelines, notifiable trials, transparency obligations, safety reporting, and labelling updates. Listeners will gain insight into how these changes will affect trial set-up and operations, what to prepare for ahead of the 28 April 2026 implementation date, and where opportunities exist for faster, more predictable approvals.
- Mar 10, 202630 min
How Will the EU Biotech Act Transform Biotechnology Regulation in Europe?
In this episode of Conversations in Drug Development, host Harriet Edwards is joined by Kelsey Lennoch and Eamon McGowran to discuss the EU Biotech Act, a major regulatory proposal aimed at revitalizing Europe’s biotech sector. They explore the act’s goals to streamline clinical trial processes, harmonize regulations, and boost funding for late-stage biotech companies. The conversation highlights key changes for medicines and medical devices, the act’s potential impact on innovation and competitiveness, and the importance of ongoing engagement as the EU’s regulatory landscape evolves. For more information, visit www.boydconsultants.com.
- Oct 23, 202526 min
Navigating the FDA Landscape: More Changes, and What's Next?
In this episode, Eric Hardter and guest Kelsey Lenoch discuss recent US FDA developments, including leadership changes at CBER and CDER, staffing impacts on orphan product reviews, and the new Rare Disease Evidence Principles aimed at accelerating approvals for rare and ultra-rare conditions. They also explore evolving trial endpoints in oncology (including surrogate measures and ctDNA), transparency moves such as the public release of Complete Response Letters and the industry’s reactions, updates on the National Priority Voucher Program, and the FDA Pre-Check initiative to boost domestic drug manufacturing. Tune in for an in-depth discussion offering timely updates and expert perspectives on what may be ahead for drug development stakeholders. 🎧 Chapters Welcome and Introductions Recap and Recent US Regulatory Affairs Developments Dr. Vinay Prasad’s Removal and Return to FDA CBER New Appointments at FDA CDER FDA Staffing Shortages and Impact on Orphan Products Rare Disease Evidence Principles Announcement FDA’s Rare Disease Innovation Hub and Ultra-Rare Disease Focus Novel Endpoints in Oncology Drug Development FDA/AACR Joint Meeting on Novel Endpoints Challenges with Overall Survival as an Endpoint FDA’s Evolving Guidance on Endpoints Post-Licensure Requirements and Surrogate Endpoints Case Study: Myelofibrosis Drug and Patient-Reported Endpoints Standardization Challenges for New Endpoints Circulating Tumor DNA as a Biomarker FDA’s Release of Complete Response Letters – Phase Two Pros and Cons of Public Complete Response Letters Industry Pushback and Sponsor Transparency Case Study: Lycos Therapeutics and Psychedelic Drug Approval Accessing and Mining Complete Response Letter Data National Priority Voucher Program Update FDA Pre-Check Program for Domestic Manufacturing Closing Remarks and Future Outlook
- Aug 26, 202539 min
At the forefront of innovation: Prof Alan Boyd reflects on the last 20 years in drug development
In this special episode of Conversations in Drug Development, host Harriet Edwards sits down with Professor Alan Boyd, founder and CEO of Boyds, to reflect on the company’s remarkable 20-year journey in drug development. Professor Boyd shares his experiences from pioneering work in gene therapy, the challenges of bringing innovative medicines forward, and the value of projects that helped pave the way for future innovation. He also highlights the importance of maintaining a patient-centric vision and the role this has played in Boyds’ success on a global scale. With stories from Boyds' involvement in pivotal projects - from the early work on the first gene therapy developed for brain cancer to contributions to the Covid-19 vaccine - the conversation offers a rare, behind-the-scenes look at how scientific innovation and evolving regulation have shaped modern medicine. Whether you’re closely involved in drug development or simply interested in how new medicines reach patients, this episode offers unique insights and reflections from someone who has spent a lifetime at the forefront of the industry. 00:00:13 – Introduction to Conversations in Drug Development 00:00:30 – Welcoming Professor Alan Boyd Back 00:01:43 – Reflecting on 20 Years of Boyds 00:02:49 – The Journey to Founding Boyds 00:06:05 – Early Challenges in Gene Therapy 00:07:26 – Manufacturing Gene Therapy Products 00:10:35 – Achievements in Cell and Gene Therapy 00:15:39 – Highlights from Two Decades 00:19:46 – Changes in Drug Development 00:23:32 – Evolution of Clinical Trials 00:28:17 – The Role of the Team at Boyds 00:31:43 – Personal Interests Beyond Medicine 00:38:12 – Future of Drug Development 00:38:42 – Closing Thoughts and Reflections
- Jul 15, 202535 min
Navigating the New FDA Landscape: Opportunities and Challenges Ahead
In the latest episode of Conversations in Drug Development, Dr Katherine Bowen and Dr Eric Hardter discuss the ever-changing US regulatory landscape under the new administration, including new leadership and staff turnover, and their impact on drug development. They examine the FDA's cautious approach to AI, efforts to reduce animal testing, and the new National Priority Voucher Program aimed at expediting drug approvals. Tune in for an in-depth discussion that offers timely updates and expert perspectives on what might be in store for drug development stakeholders. EPISODE OUTLINE 00:00:14 – Welcome to Conversations in Drug Development 00:01:16 – US Regulatory Environment Update 00:02:35 – Changes in FDA Leadership 00:03:19 – The Impact of Staffing Changes 00:05:54 – New Perspectives with Vinay Prasad 00:07:50 – Future of Cell and Gene Therapy Approvals 00:10:03 – Market Reactions and Funding Concerns 00:11:45 – Implications of FDA Cuts 00:12:29 – Marty McCary’s Vision for the FDA 00:14:46 – Navigating Conflicting Perspectives 00:15:45 – FDA Workforce and Operational Changes 00:17:21 – Review Process and Efficiency Challenges 00:20:43 – ELSA: AI in FDA Operations 00:22:54 – Reducing Animal Testing in Drug Development 00:25:05 – National Priority Voucher Programme Insights 00:31:21 – Future Outlook and Next Steps
Get Conversations in Drug Development summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Podcasts in similar categories.
The Jamie Kern Lima Show
Entrepreneur Jamie Kern Lima interviews experts and celebrities about overcoming self-doubt and building self-belief.
The Mel Robbins Podcast
A motivational podcast offering research-backed tools and personal stories to help listeners make positive life changes.
We're Out of Time
Discusses the fentanyl crisis, mental health, and resilience through interviews with recovery experts, survivors, and public figures.
Hidden Brain
Explores human behavior and the unconscious patterns that shape our decisions, relationships, and society through science and storytelling.
Biohack-it
A weekly exploration of biohacking, holistic health, and science-driven strategies for optimizing physical and mental well-being.
Something You Should Know
Explores practical wisdom and expert insights to help listeners improve their lives, careers, and relationships.
Tony Mantor: Why Not Me ?
Explores autism, mental health, and human stories to promote understanding, challenge stigma, and support neurodiversity.
The Dylan Gemelli Podcast
Experts in health, fitness, and biohacking share science-backed strategies to improve well-being and performance.
About Conversations in Drug Development
Welcome to Conversations in Drug Development, brought to you by the team at Boyds. This podcast is for our fellow community of scientists and clinicians working in the wonderful world of cell and gene therapy and drug development.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Conversations in Drug Development in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Conversations in Drug Development daily summary?
It's a free AI-powered email that summarizes new episodes of Conversations in Drug Development as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Conversations in Drug Development podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Conversations in Drug Development product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Boyds.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does Conversations in Drug Development release new episodes?
Conversations in Drug Development publishes monthly. Our AI generates a summary within hours of each new episode.
What topics does Conversations in Drug Development cover?
Conversations in Drug Development covers topics including Science, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Conversations in Drug Development summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.